Onconova Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Steven M. Fruchtman
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12 Penns Trail Newtown PA United States of America 18940
- IPO Date
- Jul 25, 2013
- CIK
- 0001130598
- Website
- onconova.com
- Similar Companies
- Business
- Onconova Therapeutics, Inc. (NASDAQ: ONTX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel targeted anti-cancer agents that disrupt specific cellular pathways critical for cancer cell proliferation; its lead product candidates include narazaciclib (formerly ON 123300), a proprietary multi-kinase inhibitor evaluated in Phase 1 dose-escalation and expansion studies in the United States and China for advanced solid tumors including low-grade endometrioid endometrial cancer in combination with letrozole, and oral rigosertib, investigated as monotherapy for recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma and in combination with PD-1 checkpoint inhibitors such as nivolumab or pembrolizumab for IO-refractory KRAS-mutated non-small cell lung cancer and malignant melanoma. Founded in 1998 and headquartered in Newtown, Pennsylvania, the company operates primarily in the United States with clinical trials extending to China and targets oncology indications such as myelodysplastic syndromes, endometrial cancer, lung cancer, melanoma, and rare cancers. In April 2024, Onconova completed a transformative business combination through its acquisition of 100% of Trawsfynydd Therapeutics, Inc., a developer of next-generation antivirals, forming Traws Pharma, Inc. (NASDAQ: TRAW), which trades under the new ticker and secured approximately $28 million in cash via a $14 million private placement led by OrbiMed and Torrey Pines to advance narazaciclib's dose-ranging, rigosertib programs, and Trawsfynydd's viroksavir for influenza and travaltrelvir for COVID-19 toward Phase 2 studies in the second half of 2024. This merger positions the combined entity as a virology and oncology platform with diversified pipelines, including narazaciclib's ongoing Phase 1 extension for recommended Phase 2 dose determination expected in early 2025 and rigosertib's investigator-sponsored trials showing promising target engagement and safety profiles without significant neutropenia or diarrhea.
Traws Pharma Announces New Employee Inducement Grants
Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024
Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference
Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL
Onconova Expands Leadership Team with Two Key Appointments
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript
Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript
Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates
Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023
3 Penny Stocks To Buy According To Analysts, Targets Up To 1,029%
5 Hot Penny Stocks To Watch With The Stock Market Down This Week
Penny Stocks To Buy Now? 5 With Big News Today
Onconova Therapeutics, Inc. (ONTX) Q4 2022 Earnings Call Transcript